We claim:

1. A combination comprising a histamine-3 receptor inverse agonist, an acetylcholinesterase inhibitor and a NMDA receptor antagonist; wherein the histamine-3 receptor inverse agonist is selected from the group consisting of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1 or 2, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

4. The combination as claimed in any one of claims 1 to 3, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

5. The combination as claimed in any one of claims 1 to 4, wherein the pharmaceutically acceptable salt of the histamine-3 receptor inverse agonist is selected from the group consisting of
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.

6. The combination as claimed in any one of claims 1 to 5, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

7. The combination as claimed in any one of claims 1 to 6, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.

8. The combination as claimed in any one of claims 1 to 7, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

9. The combination as claimed in any one of claims 1 to 8, wherein the NMDA receptor antagonist is memantine hydrochloride.

10. A combination comprising N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, donepezil hydrochloride and memantine hydrochloride.

11. The combination as claimed in any one of claims 1 to 10, for use in therapy.

12. Use of the combination as claimed in any one of claims 1 to 10 in the manufacture of a medicament for the treatment of cognitive disorders in a patient.

13. The use as claimed in claim 12, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

14. A compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof for use in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist for use in therapy.

15. The compound for use as claimed in claim 14, as an adjunct treatment for Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.

16. The compound for use as claimed in claim 14 or claim 15, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

17. The compound for use as claimed in any one of claims 14 to 16, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

18. Use of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.

19. The use as claimed in claim 18, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

20. The use as claimed in claim 18 or claim 19, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

21. The use as claimed in any one of claims 18 to 20, wherein 0.1 mg to 100 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

22. The use as claimed in any one of claims 18 to 21, wherein 0.1 mg to 60 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

23. The use as claimed in any one of claims 18 to 22, wherein 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

24. The use as claimed in any one of claims 19 to 23, wherein 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

25. The use as claimed in any one of claims 20 to 24, wherein 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

26. A pharmaceutical composition comprising the combination as claimed in any one of claims 1 to 10, and pharmaceutically acceptable excipients or a combination thereof.

27. The pharmaceutical composition as claimed in claim 26, for use in therapy.

28. Use of the pharmaceutical composition as claimed in claim 26 in the manufacture of a medicament for the treatment of cognitive disorders selected from the group consisting of Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

29. The pharmaceutical composition as claimed in claim 26, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 100 mg.

30. The pharmaceutical composition as claimed in claim 26 or claim 29, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 60 mg.

31. The pharmaceutical composition as claimed in any one of claims 26, 29 and 30, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 30 mg.

32. The pharmaceutical composition as claimed in any one of claims 26 and 29 to 31, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof and is present in an amount of 2 mg to 30 mg.

33. The pharmaceutical composition as claimed in any one of claims 26 and 29 to 32, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof and is present in an amount of 1 mg to 40 mg.

34. The use as claimed in claim 18, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

35. The use as claimed in claim 18, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.